Immutep Ltd Total Liabilities
Immutep Ltd total liabilities. Based on the latest financial reports, Immutep Ltd (IMM) has total liabilities worth AU$13.35 Million AUD (≈ $9.44 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Immutep Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Immutep Ltd (2000–2025)
Total liabilities of Immutep Ltd from 2000 to 2025. This chart illustrates how Immutep Ltd's total liabilities have evolved over time, based on quarterly financial data.
Immutep Ltd Competitors by Total Liabilities
The table below lists competitors of Immutep Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
OPCOM Holdings Bhd
KLSE:0035
|
Malaysia | RM106.72 Million |
|
Formetal Co. Ltd
KQ:119500
|
Korea | ₩12.34 Billion |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
Korea | ₩29.68 Billion |
|
Maniker F & G Co. Ltd
KQ:195500
|
Korea | ₩44.83 Billion |
|
Aciselsan Acipayam Seluloz Sanayi Ve Ticaret AS
IS:ACSEL
|
Turkey | TL352.95 Million |
|
Kidoz Inc
V:KIDZ
|
Canada | CA$2.19 Million |
|
SP Systems Co.Ltd
KQ:317830
|
Korea | ₩30.48 Billion |
|
Protasco Bhd
KLSE:5070
|
Malaysia | RM529.18 Million |
Liability Composition Analysis (2000–2025)
This chart breaks down Immutep Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IMM total asset value.
Liquidity & Leverage Metrics
Immutep Ltd Total Liabilities Ratios Explained
Immutep Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.35 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immutep Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immutep Ltd (2000–2025)
The table below shows the annual total liabilities of Immutep Ltd from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$13.35 Million ≈ $9.44 Million |
+10.70% |
| 2024-06-30 | AU$12.06 Million ≈ $8.53 Million |
+9.82% |
| 2023-06-30 | AU$10.98 Million ≈ $7.77 Million |
+35.68% |
| 2022-06-30 | AU$8.09 Million ≈ $5.73 Million |
-7.61% |
| 2021-06-30 | AU$8.76 Million ≈ $6.20 Million |
-34.13% |
| 2020-06-30 | AU$13.30 Million ≈ $9.41 Million |
-17.68% |
| 2019-06-30 | AU$16.15 Million ≈ $11.43 Million |
+19.86% |
| 2018-06-30 | AU$13.48 Million ≈ $9.54 Million |
+59.84% |
| 2017-06-30 | AU$8.43 Million ≈ $5.97 Million |
+16.51% |
| 2016-06-30 | AU$7.24 Million ≈ $5.12 Million |
+14.98% |
| 2015-06-30 | AU$6.29 Million ≈ $4.45 Million |
+125.93% |
| 2014-06-30 | AU$2.79 Million ≈ $1.97 Million |
-21.88% |
| 2013-06-30 | AU$3.57 Million ≈ $2.52 Million |
-19.95% |
| 2012-06-30 | AU$4.45 Million ≈ $3.15 Million |
+75.28% |
| 2011-06-30 | AU$2.54 Million ≈ $1.80 Million |
+14.29% |
| 2010-06-30 | AU$2.22 Million ≈ $1.57 Million |
+228.41% |
| 2009-06-30 | AU$677.10K ≈ $479.09K |
+260.51% |
| 2008-06-30 | AU$187.82K ≈ $132.89K |
-32.49% |
| 2007-06-30 | AU$278.21K ≈ $196.85K |
-73.33% |
| 2006-06-30 | AU$1.04 Million ≈ $738.22K |
+32.38% |
| 2005-06-30 | AU$788.11K ≈ $557.64K |
+22.76% |
| 2004-06-30 | AU$642.00K ≈ $454.26K |
-26.63% |
| 2003-06-30 | AU$875.00K ≈ $619.12K |
+87.77% |
| 2002-06-30 | AU$466.00K ≈ $329.72K |
+356.86% |
| 2001-06-30 | AU$102.00K ≈ $72.17K |
-53.42% |
| 2000-06-30 | AU$219.00K ≈ $154.96K |
-- |
About Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes… Read more